EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis

被引:9
作者
Tsai, Jeng-Shiuan [1 ,2 ]
Su, Po-Lan [1 ]
Yang, Szu-Chun [1 ]
Chang, Chao-Chun [3 ]
Lin, Chia-Ying [4 ]
Yen, Yi-Ting [3 ]
Tseng, Yau-Lin [3 ]
Lai, Wu-Wei [3 ]
Lin, Chien-Chung [1 ,2 ,5 ]
Su, Wu-Chou [1 ,2 ,6 ]
机构
[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Coll Med, 138 Sheng Li Rd, Tainan 704, Taiwan
[2] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Surg, Coll Med, Tainan, Taiwan
[4] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Med Imaging, Coll Med, Tainan, Taiwan
[5] Natl Cheng Kung Univ, Inst Biochem & Mol Biol, Coll Med, Tainan, Taiwan
[6] Natl Cheng Kung Univ, Ctr Appl Nanomed, Tainan, Taiwan
关键词
Bevacizumab; NSCLC; TKI; EGFR mutation; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; PHASE-III TRIAL; OPEN-LABEL; 1ST-LINE TREATMENT; CARBOPLATIN-PACLITAXEL; ASIAN PATIENTS; GEFITINIB; ERLOTINIB; CHEMOTHERAPY;
D O I
10.1016/j.jfma.2021.03.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recent study showed that the combination of erlotinib and bevacizumab had bet -ter disease control than erlotinib monotherapy in patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). However, there is lack of real-world evidence for this therapeutic regimen. We aimed to compare outcomes between patients with EGFR mutant NSCLC treated with EGFR-tyrosine kinase inhibitors (TKI) and bev-acizumab and those treated with EGFR-TKI alone in a real-world setting. Methods: Patients with advanced EGFR-mutant NSCLC who received first-line EGFR-TKI in a tertiary referral center from October 1, 2013 to December 31, 2019 were retrospectively analyzed. We performed 1:2 propensity score-matching: one EGFR-TKI and bevacizumab recipient with two patients who received EGFR-TKI alone. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method. The prognostic factors were analyzed using Cox proportional hazards regression analysis. Results: Total 313 patients were enrolled. After propensity score matching, 45 patients who received first-line EGFR-TKI and bevacizumab and 89 patients who received EGFR-TKI alone were analyzed. The combination group showed improved PFS (17.0 vs. 11.0 months; hazard ratio [HR] = 0.48; p = 0.002) compared to the monotherapy group. In subgroup analysis of patients with an L858R mutation, the combination group showed longer PFS (23.1 vs. 10.7 months; HR = 0.40; p = 0.011) and OS (not reached vs. 40.6 months; HR = 0.27; p = 0.040) than the EGFR-TKI monotherapy group. Conclusion: Our data suggest that the combination of EGFR-TKI and bevacizumab could improve PFS in patients with EGFR-mutant NSCLC. In patients harboring L858R mutation, the combination therapy provides better OS than TKI alone. Copyright 2021, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:1729 / 1739
页数:11
相关论文
共 37 条
[1]  
Austin PC, 2008, STAT MED, V27, P2037, DOI 10.1002/sim.3150
[2]   Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer [J].
Blumenthal, G. M. ;
Gong, Y. ;
Kehl, K. ;
Mishra-Kalyani, P. ;
Goldberg, K. B. ;
Khozin, S. ;
Kluetz, P. G. ;
Oxnard, G. R. ;
Pazdur, R. .
ANNALS OF ONCOLOGY, 2019, 30 (05) :830-838
[3]   Usefulness of quantitative hepatitis B surface antigen testing in hepatitis B community-based screening [J].
Chang, Kao-Chi ;
Lee, Chih-Yi ;
Chang, Te-Sheng ;
Hung, Chao-Hung ;
Chen, Wei-Ming ;
Chen, Mei-Yen ;
Huang, Tung-Jung ;
Chiu, Wen-Nan ;
Hu, Jing-Hong ;
Lin, Yu-Chih ;
Huang, Wei-Cheng ;
Hsu, Nien-Tzu ;
Lu, Sheng-Nan .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2021, 120 (02) :847-853
[4]   Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib [J].
Gilmer, Tona M. ;
Cable, Louann ;
Alligood, Krystal ;
Rusnak, David ;
Spehar, Glenn ;
Gallagher, Kathleen T. ;
Woldu, Ermias ;
Carter, H. Luke ;
Truesdale, Anne T. ;
Shewchuk, Lisa ;
Wood, Edgar R. .
CANCER RESEARCH, 2008, 68 (02) :571-579
[5]   Sequential afatinib and osimertinib in patients withEGFRmutation-positive non-small-cell lung cancer: final analysis of the GioTag study [J].
Hochmair, Maximilian J. ;
Morabito, Alessandro ;
Hao, Desiree ;
Yang, Cheng-Ta ;
Soo, Ross A. ;
Yang, James C-H ;
Gucalp, Rasim ;
Halmos, Balazs ;
Marten, Angela ;
Cufer, Tanja .
FUTURE ONCOLOGY, 2020, 16 (34) :2799-2808
[6]   The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study [J].
Hsu, Ping-Chih ;
Huang, Chun-Yao ;
Wang, Chin-Chou ;
Kuo, Scott Chih-Hsi ;
Chu, Chia-Hsun ;
Tung, Pi-Hung ;
Huang, Allen Chung-Cheng ;
Wang, Chih-Liang ;
Chiu, Li-Chung ;
Fang, Yueh-Fu ;
Yang, Cheng-Ta .
PHARMACEUTICALS, 2020, 13 (11) :1-12
[7]   The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma [J].
Huang, Yen-Hsiang ;
Hsu, Kuo-Hsuan ;
Tseng, Jeng-Sen ;
Chen, Kun-Chieh ;
Hsu, Chia-Hung ;
Su, Kang-Yi ;
Chen, Jeremy J. W. ;
Chen, Huei-Wen ;
Yu, Sung-Liang ;
Yang, Tsung-Ying ;
Chang, Gee-Chen .
CANCER RESEARCH AND TREATMENT, 2018, 50 (04) :1294-1303
[8]   Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) [J].
Inoue, A. ;
Kobayashi, K. ;
Maemondo, M. ;
Sugawara, S. ;
Oizumi, S. ;
Isobe, H. ;
Gemma, A. ;
Harada, M. ;
Yoshizawa, H. ;
Kinoshita, I. ;
Fujita, Y. ;
Okinaga, S. ;
Hirano, H. ;
Yoshimori, K. ;
Harada, T. ;
Saijo, Y. ;
Hagiwara, K. ;
Morita, S. ;
Nukiwa, T. .
ANNALS OF ONCOLOGY, 2013, 24 (01) :54-59
[9]   Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival [J].
Lee, Chee Khoon ;
Davies, Lucy ;
Wu, Yi-Long ;
Mitsudomi, Tetsuya ;
Inoue, Akira ;
Rosell, Rafael ;
Zhou, Caicun ;
Nakagawa, Kazuhiko ;
Thongprasert, Sumitra ;
Fukuoka, Masahiro ;
Lord, Sally ;
Marschner, Ian ;
Tu, Yu-Kang ;
Gralla, Richard J. ;
Gebski, Val ;
Mok, Tony ;
Yang, James Chih-Hsin .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (06)
[10]   Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer [J].
Lee, Kangkook ;
Kim, Youjin ;
Jung, Hyun Ae ;
Lee, Se-Hoon ;
Ahn, Jin Seok ;
Ahn, Myung-Ju ;
Park, Keunchil ;
Cho, Yoon-La, I ;
Sun, Jong-Mu .
LUNG CANCER, 2019, 130 :87-92